press releases

►2022
- April
- March
- February
- January
►2021
- December
- November
- October
- September
- July
- June
- May
- April
- February
- January
►2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
►2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
►2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
►2017
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
►2016
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
►2015
- December
- November
- October
- September
- August
- July
- May
- April
- March
- February
- January
►2014
- December
- November
- October
- September
- August
- July
- June
- May
- April
- February
- January
►2013
- December
- November
- August
- July
- May
- January
►2012
- November
- August
- May
- January
►2011
- December
- November
- October
- August
- April
- March
►2010
- October
- June
►2009
- September
►2008
- November
- April
►2007
- March

May 13, 2020

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1 ST. HELIER, Jersey & SHANGHAI–(BUSINESS… Read More

learn more